There are a number of ways that regulators do that. One of them is, for example, the use of foreign decisions. There is an element there where premarket review can be incorporated from a foreign jurisdiction. Most regulatory regimes also have postmarket requirements, so that's things like vigilance of the product once it's been sold, inspections of facilities, and so on and so forth.
There are other ways that we can reduce duplication. We can have mutual recognition agreements with, again, trusted regulators on specific elements. It might be good manufacturing practices. It might be advertising and labelling and so on.
With the amount of duplication that happens, as we are in an increasingly—we've all heard this before—interconnected, globalized economy, I think there are in the future going to be even more opportunities for co-operation and collaboration among regulators. There are fora for the various different sectors. There are the PIPs for pharmaceuticals, and so forth, for different regulatory regimes.